Search

Evaluates the effect of falipamil on persistent atrial fibrillation induced by atrial pacing. Administration of the drug by slow intravenous injection; Similarity of the atrial anti-arrhythmic properties of falipamil to those of Class IA anti-arrhythmic agents; Justification of pacing-induced atrial fibrillation either because of the presence of documented atrial fibrillation or flutter or because of the possible involvement of the arrhythmia in the symptoms.

Evaluates the effect of hydroquinidine in patients with inducible ventricular tachycardias using programmed electrical stimulation. Relation of arrhythmia with coronary artery disease in patients; Method used for selection of the appropriate antiarrhythmic agent; Information on spontaneous sustained ventricular tachycardias.

The electrophysiological properties of falipamil (AQA-39), a new antiarrhythmic agent with bradycardic effect, were evaluated in 12 patients. Intravenous falipamil (1.5 mg/kg within 20 minutes) significantly prolonged sinus cycle length (control, 862 ± 148 msec; Falipamil, 941 ± 170 msec). The PR interval was significantly shorter due to AH interval shortening (P < 0.004). The antegrade Wenckebach point occurred at a higher rate. These findings were ascribed to an anticholinergic effect. The major electrophysiological findings included significant prolongation of the refractory periods of atrium and ventricle, whereas those of the AV node were not affected. Retrograde ventriculoatrial conduction present in 8 patients was not altered. In conclusion falipamil prolongs sinus cycle length and depresses atrial and ventricular functions, which is suggestive of antiarrhythmic properties at the atrial and ventricular levels. [ABSTRACT FROM AUTHOR]